Solid Biosciences Inc. (NASDAQ:SLDB) is one of the stocks that will double in 2026. On December 4, Needham analyst Gil Blum initiated coverage of Solid Biosciences with a Buy rating and $16 price target. Blum noted that the recent deaths of two non-ambulatory Duchenne muscular dystrophy patients who received Sarepta’s drug, Elevidys, raise concerns about the treatment’s benefit-risk profile. This safety issue may create a significant opportunity for competing gene therapies, specifically citing Solid Biosc ...